CompletedPhase 3

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Singapore370 participantsStarted 2017-01

Plain-language summary

The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular hypertension.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with open angle glaucoma or ocular hypertension in both eyes Exclusion Criteria: * Patients at risk of progression of visual field loss * Patients with severe visual field defect * Patients with any diseases that preclude participation in this study for safety reasons

What they're measuring

Mean Diurnal IOP at Month 3

Timeframe: Month 3 (average of IOP at 3 time points: 09:00, 13:00, 17:00)

Trial details

NCT IDNCT02981446

SponsorSanten Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-01

Results submitted2023-08-02

View on ClinicalTrials.gov More Open Angle Glaucoma or Ocular Hypertension trials